Graft Polymer (UK) PLC (LSE:GPL) CEO Anthony Tennyson takes Proactive's Stephen Gunnion through the progress the company has made in its commercial collaboration with Awakn Life Sciences.
Tennyson explained the collaboration is aimed at developing new therapeutics for trauma-related mental health disorders, including post-traumatic stress disorder (PTSD).
He noted that Awakn has successfully identified two aminoindane chemical series as lead candidates, marking a crucial step forward in drug development. These compounds show promise in improving treatment options for conditions like PTSD, which affects millions globally.
Additionally, synthesis pathways for these compounds have been defined, ensuring scalable production as the project advances towards more rigorous pharmacological testing.
To further bolster the collaboration, Charnwood Discovery, a UK-based leader in drug discovery services, has been selected as the synthesis partner.
Also, a new provisional patent was filed on August 27 with the US Patent and Trademark Office.